According to Forbes, Akido Labs, which started as a data project at USC, has raised over $100 million to build an AI-powered medical network. After acquiring the Chaparral Medical Group in 2022, it now runs nearly 100 clinics where about 250 clinicians care for over half a million patients. Its core tech, called ScopeAI, uses an ensemble of models to guide medical assistants through patient intake and generate real-time diagnoses for doctors to review. Early results show clinics using the system have seen a 57% increase in patients, with some doctors doubling their volume. The company’s Series B round was led by Oak HC/FT, and it’s betting this “full-stack” model—where it builds the tech and delivers the care—is the key to exponential, not incremental, gains in capacity.
The Full-Stack Bet
Here’s the thing about most healthcare AI: it’s a bolt-on. A hospital buys a software suite from a vendor like Epic or Cerner and then tries to glue some AI on top. Akido’s founders realized that approach was limiting. So they did something radical for a tech company: they bought a doctor’s office. Actually, they bought a whole medical group.
This is the core of their bet. By controlling the entire stack—the clinics, the staff, the EHR, and the AI—they can align everything toward one goal: seeing more patients, faster. Their CTO calls it a “living-learning laboratory.” Basically, the doctors and nurses aren’t just users of the tech; they’re co-developers, annotating data and giving feedback as part of their daily job. That’s a level of integration you just can’t get by selling software to a busy hospital that’s already drowning in vendor contracts. It reminds me of what some analysts call the “full-stack” or “integrated” path to building a multi-product company. You build deep in one area to own the experience.
The Human-AI Interface
Now, the most fascinating part isn’t the AI itself. It’s how they’ve chosen to deploy it. They could have just built a chatbot and let patients talk to it alone. Technically simpler, right? But they didn’t. Instead, they put a “concierge” medical assistant, like DeAndre from the article, in the room. The AI listens and guides the MA, who does the intake. The doctor then reviews the AI’s note and diagnosis before ever walking in.
That’s a brilliant, and probably necessary, human buffer. It builds trust, especially with the elderly or vulnerable patients Akido serves. The MA provides the empathy and warmth; the AI provides the structure and clinical reasoning. And because the doctor makes the final call, it skirts the nightmare of FDA medical device regulation. It’s clinical decision support, not an autonomous agent. This hybrid model might be the only way this gets to scale without a huge backlash. But it also adds cost. Is a fourfold increase in doctor productivity enough to pay for that extra layer of skilled staff? Akido’s 90+ Net Promoter Score suggests patients think the trade-off for speed and attention is worth it.
The Trade-Offs and New Bottlenecks
Let’s be skeptical for a second. This sounds great for capacity, but what gets lost? The article nails the big concerns. That casual “chitchat” at the start of a visit isn’t just noise—it’s how rapport is built. If that’s systematized into an AI-guided Q&A, does care become transactional? And for doctors, the “easy” cases are often a mental break. If AI handles all the straightforward stuff, a doctor’s day could become a relentless parade of only the most complex, draining cases.
Then there’s the big, unsexy problem: bottlenecks just move elsewhere. This is classic Theory of Constraints. If a doctor can suddenly see four times as many patients, you’re going to need four times as many exam rooms. And what about the downstream work? The messages, the lab reviews, the referral processing? That administrative burden could explode. Akido is building its own EHR partly to manage this, but it’s a huge operational lift. Many legacy health systems, deeply entrenched in the “Era of Epic,” simply can’t innovate at this pace.
future”>A Glimpse of an Uneven Future
So, is this the future? In a way, Akido proves William Gibson right: the future is here, just not evenly distributed. For most Americans, getting a specialist appointment is a 100-day nightmare. At an Akido clinic, it’s supposedly next-day. That’s a staggering disparity.
The real question is which model wins. Will big health systems be forced to develop their own tech in-house again? Or will more software companies follow Akido and become care providers themselves? I think we’ll see both. But the organizations that thrive will be those that, like Akido, understand this isn’t just a tech problem. It’s about redesigning care models, rebalancing the workforce, and shifting culture. It requires owning the problem end-to-end. As the data shows, the U.S. health system is underperforming badly. The potential gains from a thoughtful, integrated approach are massive. Akido might not have all the answers, but they’re asking the right questions and building in the real world. The rest of healthcare should be paying very close attention.
